Joy Duemke: Optimizing Stem Cell Collection for Gene Therapy Success
Joy Duemke, Director of Marketing and Commercialization in North America at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“Gene therapy is creating new possibilities for patients with genetic hemoglobinopathies, but collecting sufficient, high-quality hematopoietic progenitor cells (HPCs) can be particularly challenging due to the impact of the underlying disease on mobilization.
Optimizing these procedures is an important step in helping more patients benefit from these therapies.
We appreciate AABB and presenting faculty, including Dr. John Manis, behind ‘Optimizing Apheresis Starting Material Collections for Stem Cell Gene Therapy Manufacturing for Patients with Genetic Hemoglobinopathies’ for tackling these challenges head-on to help ensure more SCD and thalassemia patients can benefit from these breakthrough therapies.
Register for the program on Wednesday, August 12, from 2:00–3:00 PM ET.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question